Edition:
United Kingdom

People: Clovis Oncology Inc (CLVS.OQ)

CLVS.OQ on NASDAQ Stock Exchange Global Select Market

20.88USD
18 Apr 2019
Change (% chg)

$0.08 (+0.38%)
Prev Close
$20.80
Open
$20.73
Day's High
$21.00
Day's Low
$19.80
Volume
334,708
Avg. Vol
601,496
52-wk High
$54.61
52-wk Low
$11.50

Klingenstein, Paul 

Mr. Paul H. Klingenstein is Independent Director of the Company. He is the Managing Partner of Aberdare Ventures, a healthcare-focused venture capital firm he formed in 1999. Prior to founding Aberdare, Mr. Klingenstein worked in venture capital with Warburg Pincus and Accel Partners, and was an advisor to the Rockefeller Foundation. Mr. Klingenstein currently serves on the boards of several private companies. Mr. Klingenstein has previously served on the boards of Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC), Aviron Inc., Conatus Pharmaceuticals Inc. (NASDAQ: CNAT), EnteroMedics Inc. (NASDAQ: ETRM), Glycomed Inc., Isis Pharmaceuticals, Inc., now Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), Pharmion Corporation (acquired in 2008), Viagene Inc., and Xomed Surgical Products Inc. He is currently a board member of the MacArthur Foundation and the London School of Hygiene and Tropical Medicine. He has also served on the boards of various educational and non-profit institutions. Mr. Klingenstein received an A.B. in anthropology from Harvard University and an M.B.A. from Stanford University.

Basic Compensation

Total Annual Compensation, USD 57,500
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 439,579
Fiscal Year Total, USD 497,079

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

M. James Barrett

533,329

Patrick Mahaffy

8,726,480

Daniel Muehl

1,861,090

Gillian Ivers-Read

2,383,880

Lindsey Rolfe

2,429,680

Robert Azelby

--
As Of  31 Dec 2017